News & Latest Announcements
Mitigating Risks: How CROs Ensure Safe CAR-T cells Trials
CAR T therapy has immense potential in autoimmune diseases like multiple sclerosis, but safety remains the central concern that guides every decision. The objective is to…
Read article
Are You Ready to Lead the Patient-Centric Revolution?
The clinical research industry stands at an inflection point, facing a choice between two distinct futures. The first path is “friendliness.” It’s the continuation of the…
Read article
Inside the Trials: Early Evidence of CAR-T cell therapy in Progressive MS
The idea of using CAR-T cell therapy for multiple sclerosis has moved from speculation to practical testing in the clinic. Early reports show that this therapeutic…
Read article
Metrics That Matter: Measuring Patient Experience in Trials
In business, the adage is simple: what gets measured gets managed. We apply this rigor to our financial performance and operational efficiency, so why not to…
Read article
CAR-T cells vs. Anti-CD20 antibodies: Breaking Through the CNS Barrier in MS
Anti-CD20 monoclonal antibodies like ocrelizumab have advanced MS treatment significantly and offered real hope to many patients. Yet, over time, their limitations have become harder to…
Read article
Co-Created Protocols: Co-Writing the Protocol with Patients
For decades, the clinical trial industry has asked patients for their data, their time, and their bodies. It’s time we started asking for their expertise. True…
Read article
Why CAR-T Cell Therapy is Redefining Autoimmune Treatment
For decades, patients with multiple sclerosis (MS) and other autoimmune diseases have relied on therapies that manage symptoms but rarely alter the long-term trajectory of disease.…
Read article
Why DCT is Not Optional. It’s an Ethical and Business Imperative
When the single biggest reason for patient dropout is the burden of travel, continuing to design every trial around a physical clinic isn’t just inefficient—it represents…
Read article
Why Biotechs Choose Specialized CROs
Biotech companies are increasingly turning to specialized contract research organizations (CROs) to handle their clinical trials, especially for complex and innovative therapies like allogeneic CAR-T. While…
Read article